Health startups look to raise big money with new stock offerings

Two biotech firms are trying to cash in on investor excitement around obesity drugs and disease-detecting technology. One company wants $533 million to develop weight-loss treatments, while another seeks $159 million to expand its diagnostic tools. Both plan to sell shares to the public soon, hoping to join the growing trend of health-related stock listings. Obesity drug research is getting a major funding boost as Kailera Therapeutics prepares to launch its initial public offering. The company has four experimental drugs in testing, including one weekly injection that’s in late-stage trials. Kailera claims its treatment could outperform all existing weight-loss medications. With shares priced between $14 and $16, the company could reach a market value of nearly $2 billion if the offering succeeds.Meanwhile, Alamar Biosciences is focusing on protein biomarkers to detect diseases earlier. The company plans to sell shares at $15 to $17 each, potentially raising $160 million. The funds would help Alamar grow its manufacturing and sales teams. Like Kailera, Alamar’s offering is expected to price on the same day, showing how closely these two companies are timing their market moves. So far this year, health companies have raised $2. 4 billion through IPOs, matching last year’s pace. But this follows three straight years of rising totals, meaning investors are still eager to bet on medical innovation. While the amounts are smaller than past peaks, the trend suggests confidence in the sector remains strong. Big investors like Bain Capital and Qatar’s sovereign fund have already signaled interest in buying shares in Kailera. If their purchases go through, Bain’s affiliates would own a third of the company. This kind of backing shows how private equity firms are still betting on biotech, even after major deals like AbbVie’s $8. 7 billion purchase of Cerevel Therapeutics in 2024.